

# Erythrocytes Membrane Alterations Reflecting Liver Damage in CCl<sub>4</sub>-Induced Cirrhotic Rats: The Ameliorative Effect of Naltrexone

Fatemeh Sarhadi Kholari<sup>1</sup>, Ahmad Reza Dehpour<sup>2</sup>, Mitra Nourbakhsh<sup>3,4</sup>, Amir Hossein Doustmotlagh<sup>1</sup>, Molood Bagherieh<sup>1</sup>, and Abolfazl Golestani<sup>1</sup>

<sup>1</sup> Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

<sup>3</sup> Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>4</sup> Metabolic Disorders Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Received: 25 Nov. 2015; Revised: 12 Jan. 2016, Accepted: 04 Feb. 2016

**Abstract-** Cirrhosis is the consequence of chronic liver disease. Deleterious effects of oxidative stress on hepatocytes may be reflected in the erythrocyte membrane. Naltrexone (NTX) has been shown to attenuate hepatocellular injury in fibrotic animal models. The aim of this study was to investigate the progressive effect of CCl<sub>4</sub> on the liver and whether the improvement of liver cirrhosis can be monitored through alterations in the erythrocyte membrane. In this study, 84 male Wistar rats were divided into 4 groups and received reagents (i.p.) as follows: 1- CCl<sub>4</sub>, 2- NTX + CCl<sub>4</sub>, 3- Mineral Oil (M), and 4- NTX + M. After 2, 6 and 8 weeks, the blood and liver tissue samples were collected. Plasma enzyme activities, the content of erythrocyte GSH and some membrane compositions, including protein carbonyl, protein sulfhydryl, and malondialdehyde were assessed. After 6 and 8 weeks, plasma enzyme activities and the content of protein carbonyl were higher in CCl<sub>4</sub> group significantly, as compared to other groups ( $P < 0.001$ ). NTX significantly diminished protein carbonyl and plasma enzyme activities ( $P < 0.001$ ). GSH did not change until the 6<sup>th</sup> week. However, CCl<sub>4</sub>+NTX increased it significantly as compared to CCl<sub>4</sub> group ( $P < 0.05$ ). Protein sulfhydryl showed changes in NTX+CCl<sub>4</sub> group which indicated a significant increase in protein sulfhydryl content in a 6<sup>th</sup> week compared to CCl<sub>4</sub> group ( $P < 0.05$ ). MDA did not show any significant alteration. CCl<sub>4</sub>-induced cirrhosis is accompanied by increased content of oxidative stress markers, especially protein carbonyl of RBC membrane and plasma enzyme activities. This study shows that the progression of liver cirrhosis and the ameliorative effect of NTX can be followed through alterations of these markers.

© 2016 Tehran University of Medical Sciences. All rights reserved.

*Acta Med Iran*, 2016;54(10):631-639.

**Keywords:** Cirrhosis; Carbon tetrachloride; Naltrexone; Oxidative stress

## Introduction

Liver cirrhosis is a major yet largely preventable and under-appreciated cause of global health loss and has emerged as a major cause of the global health burden (1). Liver disease is now the fifth most common cause of death (2). This liver injury is associated with abnormalities in the systemic circulation (3) and increased risk of hepatocellular carcinoma (4,5). Despite increasing knowledge about molecular and cellular mechanisms involved in liver carcinogenesis (6), the only hepatocellular carcinoma (HCC) curative treatment is transplantation (7). Liver biopsy is the best way that provides valuable information for making treatment

decisions, but it is invasive, costly, difficult to repeat and has life-threatening complications (8,9). Accordingly, non-invasive tools to assess liver disease, especially its progression or remission, have been largely needed. Some procedures have been introduced as more safe ways for recognizing and following liver cirrhosis like FibroTest (FT); combination of serum markers based on five and six biochemical markers (10); or serum markers of fibrogenesis (8), but they have shown only a moderate correlation with histological changes in fibrosis and cirrhosis (8,11). Considering the important role of oxidative stress in the pathogenesis of cirrhosis (12,13), it seems that systemic markers of oxidative stress could reflect the intensity of disease

**Corresponding Author:** A. Golestani

Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran  
Tel: +98 21 88991592, Fax: +98 21 88991593, E-mail address: golsetan@tums.ac.ir

## Erythrocytes membrane in cirrhotic rats

progress in the liver (14-16).

The biological membrane which is composed of oriented proteins and lipids which have a dynamic and semi-fluid structure and even minor changes in its fluidity may cause abnormal function and pathological consequences (17). Reactive oxygen species (ROS)-mediated lipid peroxidation leads to accumulation of cytotoxic products such as MDA and 4-hydroxy alkenals such as 4-hydroxy-nonenal (4-HNE) (18) which impair various cellular functions (16,19). Proteins may also be damaged by ROS leading to structural changes and loss of function (20). Oxidation of proteins leads to carbonyl residue formation which is an irreversible reaction. So the presence of carbonyl groups in proteins is a marker of ROS-mediated protein oxidation (21). Changes in protein sulfhydryl oxidation are also suggested to play an important role in the pathogenesis of hepatotoxins (22). Erythrocyte membrane alterations have been shown to be of useful tools and peripheral biomarkers of some diseases (23). Studies also have shown that lipid and protein oxidation in erythrocyte membrane, as well as GSH content alteration, occurs in erythrocytes in liver fibrosis and cirrhosis, although controversial results have also been reported (24-26).

Carbon tetrachloride (CCl<sub>4</sub>); a well-known hepatotoxin (27), which is widely used to induce hepatic cirrhosis in experimental models (28-30), was utilized in the current study. Cytochrome P450 system in liver microsomes converts CCl<sub>4</sub> to free radicals which are highly reactive and cause lipid peroxidation and toxicity (31).

It has been shown that endogenous opioids may modulate oxidative stress and therefore affect cell proliferation and survival. Naltrexone (NTX) is a  $\mu$ -opioid receptor antagonist and blocks endogenous opioids receptors which are increased during a liver injury (32). Also, it has been shown that NTX ameliorates liver injury in many animal models of cirrhosis (33-35). There is evidence that NTX normalizes hepatic reduced glutathione (GSH) and lipid peroxidation (LPO) levels and meanwhile, suppresses hepatic cell apoptosis in chronic cholestasis (36). Although increased oxidative stress in liver cirrhosis has been shown in previous studies (37), it is not yet clear whether amelioration of liver cirrhosis in different stages of the disease is accompanied by an improvement in oxidative stress status and if NTX is beneficial in this regard. Thus, in the current study, we examined the changes in oxidative stress markers including GSH, MDA, and protein carbonyl and sulfhydryl content in

erythrocyte membrane during progression of liver cirrhosis and the consequence of blocking opioid receptors by NTX in CCl<sub>4</sub>-induced cirrhotic rats to clarify if progression of liver cirrhosis by CCl<sub>4</sub> and especially its amelioration by NTX can be monitored via these oxidative stress markers.

## Materials and Methods

### Chemicals

All chemicals were obtained from Sigma-Aldrich (unless specified), at the appropriate grades.

### Animal model and sample collection

Male Albino-Wistar rats weighing 200-250 g, were used in this study. The rats were housed in an environment with a temperature of 23±2°C, 50±5% humidity, and a 12 h light/dark cycle. They had free access to tap water and standard chow. All procedures were performed according to the Animal Care Guidelines published by the National Institutes of Health in the USA and were approved by the ethics committee of Tehran University of Medical Sciences. Treated animals were randomly assigned to 4 groups (21 Rat/group) and these 21 Rats divided into 3 subgroups (7 Rat/subgroup) to be sacrificed in 3 different times after beginning of the study. The animal receives substrates as follows: (I) CCl<sub>4</sub> (test; treated with CCl<sub>4</sub> 750 mg/kg, dissolved in 1 ml mineral oil *i.p.* every other day), (II) NTX+CCl<sub>4</sub>; (treated with CCl<sub>4</sub> 750 mg/kg, dissolved in 1 ml mineral oil *i.p.* every other day and NTX 10 mg/kg dissolved in normal saline daily), (III) mineral oil (control; treated with 1 ml mineral oil *i.p.* every other day), (IV) NTX + mineral oil (treated with 1 ml mineral oil *i.p.* every other day and NTX 10 mg/kg dissolved in normal saline daily). Blood and liver tissue samples were collected at 2, 6 and 8 weeks after the beginning of injections.

### Histological evaluation

Liver tissue samples were taken immediately after blood collecting and surgical operation of rats under general anesthesia by ether and were fixed in 10% formaldehyde solution, followed by fixing in 70% alcohol. After embedding in paraffin, the samples were sectioned and stained with haematoxylin-eosin (H & E) reagent. The sections were studied under a light microscope.

### Plasma biochemical measurements

Blood was collected in heparin-containing tubes,

centrifuged at 3000 rpm for 10 min at 4° C, plasma, and buffy coat were removed, and plasma was kept frozen at -80°C for analysis. The activity of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were measured using commercially available kits (Pars Azemoon).

#### Preparation of erythrocyte membrane

Erythrocyte membrane ghosts were prepared according to Dodge *et al.*, with a little modification (38). Briefly, erythrocytes were washed four times with cold (4°C) phosphate-buffered saline (155 mM, pH 7.4). Hypotonic lysis of cells was performed in cold 5 mM sodium phosphate buffer (pH 8.0) followed by centrifugation (30 min, 4°C, 20000×g). The supernatant (hemolysate) was decanted carefully, and the ghosts were washed four times subsequent to hemolysis. Biuret method was used for estimating total protein content of the erythrocyte membrane with bovine serum albumin (BSA) as a standard (39).

#### Protein carbonyl content

Protein carbonyl contents in erythrocyte membrane were evaluated using 2,4-dinitrophenylhydrazine (DNPH) assay with slight modifications (40). The erythrocyte ghosts containing 0.5 mg protein were precipitated with 10% trichloroacetic acid, (4:1, w/v) and centrifuged at 4 °C for 5 min at 11000×g. Supernatant was discarded, and the pellets were resuspended in 500 µl of 10 mM DNPH in 2 M HCl and allowed to rest at room temperature for 60 min, vortexing every 10-15 min to facilitate the reaction with proteins. Proteins were precipitated with 50% trichloroacetic acid and centrifuged at 4° C for 5 min at 11000×g. After washing the pellet with 500 µl ethanol:ethyl acetate (1:1, v/v) three times, the insoluble materials were removed by centrifugation and dissolved in 0.6 ml of 6 M guanidine hydrochloride at 37° C. The absorbance of the samples was measured at 370 nm. Carbonyl group content was calculated using a molar absorption coefficient of  $2.2 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$  and expressed as µmol/mg protein.

#### Protein sulfhydryl measurement

Erythrocyte membrane protein sulfhydryl content was determined using the Ellman reagent containing 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (41). Briefly, erythrocyte membrane ghost samples containing 0.5 mg protein were denatured with sodium dodecyl sulfate and reacted with Ellman reagent. The absorbance of the resulting thiophenylate anions was measured at

412 nm. The sulfhydryl content was calculated using molar absorption coefficient of  $1.36 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$  and expressed as µmol/mg protein.

#### Reduced glutathione (GSH) assay

The concentration of GSH was assayed using GSH Assay Kit (BioVision, Mountain View, CA, USA). The concentration of GSH was expressed as µmol/gHb.

The concentrations of hemoglobin in the hemolysate samples were measured according to Drabkin's method (42).

#### Lipid peroxidation measurement

Lipid peroxidation was estimated by measuring malondialdehyde (MDA) formation (43). Briefly, erythrocyte membrane ghosts containing 0.5 mg protein, were suspended in a reagent with 15% w/v trichloroacetic acid, 0.375% w/v thiobarbituric acid and 0.25 N HCl. The solution was heated in a boiling water bath for 15 min. After cooling, the precipitate was removed by centrifugation. Absorbance was measured at 535 nm. MDA concentration was calculated using its molar absorption coefficient of  $1.56 \times 10^5 \text{ M}^{-1} \text{ cm}^{-1}$  (44) and expressed as µmol/mg protein.

#### Statistical analysis

Results are presented as mean±SEM for at least two repeats of the experiment. Statistical significance was assessed by ANOVA, followed by Tukey's post-hoc test. A *P*.value of 0.05 or less was considered statistically significant.

## Results

#### Biochemical parameters


As shown in Table 1, the plasma activity of ALT, ALP and GGT were significantly higher in the CCl<sub>4</sub> group as compared to those in other groups (*P*<0.05) indicating the progression of liver injury. The results showed that NTX was able to partially reverse the increased GGT activity and could significantly reverse the increased ALP and ALT activities in NTX+CCl<sub>4</sub> group (*P*<0.001); revealing protective and to some extent, curative effect of NTX against the stress caused by CCl<sub>4</sub>.

#### Membrane protein modification


Erythrocyte membrane protein carbonyl content was dramatically increased in the CCl<sub>4</sub> group with a peak level at the 6<sup>th</sup> week. This value was significantly diminished in the CCl<sub>4</sub>+NTX group as compared to CCl<sub>4</sub> group

## Erythrocytes membrane in cirrhotic rats

( $P < 0.001$ ), however, it was still higher than the control group ( $P < 0.01$ ). Protein carbonyl levels were decreased especially at week 8 ( $P < 0.001$ ) and returned to that of control levels in  $\text{CCl}_4 + \text{NTX}$  group (Figure 1a).



**Figure 1a.** Protein carbonyl level of erythrocyte membrane



**Figure 1b.** Protein sulphydryl level of erythrocyte membrane


Erythrocyte membrane protein carbonyl (a) and protein sulphydryl (b) in  $\text{NTX}$  treated  $\text{CCl}_4$ -induced cirrhotic rats.  $\text{CCl}_4$  and  $\text{CCl}_4 + \text{NTX}$  are test groups. \*, Comparison of the groups with control with  $P < 0.05$ , #, comparison of two test groups with  $P < 0.05$  at the same week after injection. Repetition of \* and # signs two times means  $P < 0.01$  and three times means  $P < 0.001$ . Abbreviations are as in Table 1.

There were no significant changes in protein sulphydryl level of erythrocyte membrane samples in  $\text{CCl}_4$  treated rats in comparison with control group. However, there was a significant increase in protein sulphydryl content of the  $\text{NTX} + \text{CCl}_4$  group at week 6 compared to  $\text{CCl}_4$  group ( $P < 0.05$ ) (Figure 1b).

## Membrane lipid peroxidation

$\text{NTX}$  slightly decreased  $\text{CCl}_4$ -induced MDA

production in  $\text{CCl}_4 + \text{NTX}$  group but this effect was not significant as compared to both control and  $\text{CCl}_4$  groups (Figure 2) and no increase was observed in any groups in comparison to that of the control ( $P < 0.05$ ).




**Figure 2.** MDA level of erythrocyte membrane

Malondialdehyde (MDA) content as an indication of lipid peroxidation of erythrocyte membrane content in  $\text{NTX}$  treated  $\text{CCl}_4$ -induced cirrhotic rats.  $\text{CCl}_4$  and  $\text{CCl}_4 + \text{NTX}$  are test groups.

Abbreviations are as in Table 1.

## Glutathione content

GSH content did not show any significant changes in  $\text{CCl}_4$  group as compared to the control group, but the results indicate that  $\text{NTX}$  significantly increased it when administrated simultaneously with  $\text{CCl}_4$  significantly, especially 8 weeks after injection as compared to control ( $P < 0.05$ ) and  $\text{CCl}_4$  groups ( $P < 0.01$ ) (Figure 3).




**Figure 3.** GSH level of erythrocyte membrane

Reduced glutathione (GSH) content in  $\text{NTX}$  treated  $\text{CCl}_4$ -induced cirrhotic rats.  $\text{CCl}_4$  and  $\text{CCl}_4 + \text{NTX}$  are test groups. \*, comparison of the groups with control with  $P < 0.05$ , #, comparison of two test groups with  $P < 0.01$  at the same week after injection. Abbreviations are as in Table 1.

### Histological study

Photomicrographs of hematoxylin-Eosin stained sections of the liver tissues are shown in Figure 4. In control animals, the architecture of the hepatic parenchyma tissue was normal. Slight necrosis and granules of fat were observed in CCl<sub>4</sub> treated rats after 2 weeks. At the same week, some areas of necrosis and hyperemia were noticed in NTX+CCl<sub>4</sub> group. In the 6<sup>th</sup> week, infiltration of inflammatory cells was evident, and the cells were surrounded by blood. Comparison of the tissue samples from the CCl<sub>4</sub> and NTX+CCl<sub>4</sub> groups

during the 6<sup>th</sup> week showed less fibrosis in the latter, which confirms a protective role for NTX. After 8 weeks, extensive bridging fibrosis (portal to portal and portal to central linkage with fibrotic bands), necrosis and inflammation were observed, and many inflammatory cells were seen. These histopathological events are in line with the biochemical changes, and prove cirrhosis progression in CCl<sub>4</sub> treated animals after eight weeks. At the 8<sup>th</sup> week, severe hyperemia and increased kupffer cells are visible in the NTX+CCl<sub>4</sub> group.



**Figure 4.** Hematoxylin-Eosin staining of liver tissue from the control group, CCl<sub>4</sub>-treated and NTX+CCl<sub>4</sub> treated groups after 2, 6, and 8 weeks of injection. Abbreviations are as in Table 1.

**Table 1. Biochemical parameters**

Enzymes	Time (week 2)			
	Control	CCl <sub>4</sub>	CCl <sub>4</sub> +NTX	NTX
ALT (U/l)	25.47±2.01	64.84 ±8***	181.93±8***	18.35±1.63
ALP (U/l)	159.35±6.94	237±21	312±14**	125.44±6.89
GGT (U/l)	3.58±0.36	7.7±091	8.56±0.28	7.1±0.84
Enzymes	Time (week 6)			
	Control	CCl <sub>4</sub>	CCl <sub>4</sub> +NTX	NTX
ALT (U/l)	86.36±3.39	251.28±15***	209.42±17***	25.46±3.57
ALP (U/l)	118.55±9.25	409.3±42***	489.08±34***	147.77±17.57
GGT (U/l)	5.63±0.46	12.55±1.03***	10.51±0.85***	4.06±0.67
Enzymes	Time (week 8)			
	Control	CCl <sub>4</sub>	CCl <sub>4</sub> +NTX	NTX
ALT (U/l)	13.36±29	251.87±12***	129.02±10***###	15.46±0.92
ALP (U/l)	144.05±13.47	582.8±47***	351.53±41***###	143.36±10.05
GGT (U/l)	7.38±1.7	11.16±0.76	10.72±1.36***	1.9±0.41

Table 1 shows biochemical parameters of control and test groups. Data are presented as mean±SEM. Asterisks denote significant differences from the control group, \* and # denote significant differences between NTX+CCl<sub>4</sub> and CCl<sub>4</sub> groups as the same week. *P*<0.05, \*\* *P*<0.01, \*\*\* *P*<0.001, # *P*<0.05, ## *P*<0.01, ### *P*<0.001. GGT: gamma glutamyl transferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase;

CCl<sub>4</sub>: carbon tetrachloride; NTX: Naltrexone; M: mineral oil.

All enzymes activities were significantly higher in CCl<sub>4</sub> groups indicating the progression of liver injury. The results showed that NTX was able to partially reverse the increased GGT activity and can significantly reverse the increased ALP and ALT activities in NTX+CCl<sub>4</sub> group.

### Discussion

The imbalance between the production of free radicals and antioxidants results in pathological damages (12). In the current study, we aimed to induce cirrhosis with CCl<sub>4</sub> which is widely used to compel hepatic fibrosis and cirrhosis in experimental models (29). In CCl<sub>4</sub>-induced cirrhotic rats, hepatic responses to CCl<sub>4</sub> administration are similar to those of human hepatic cirrhosis (30). Liver injury induced by CCl<sub>4</sub> is the best characterized system of xenobiotic-induced hepatotoxicity in living systems (7). Since the development of liver cirrhosis is a progressive procedure, cross-sectional assessment of different markers may not give enough insight for evaluation of disease progression. Thus we used animal models of liver damage from early to advanced cirrhosis to give a better perspective of biochemical alterations during stages of the disease progression and amelioration. We found significant increases in the activity of enzymes ALT, ALP, and GGT in this model, indicating severe impairment of the liver function (45). These alterations were correlated with the histological documents provided by H and E staining of the liver tissues from the experimental and control groups which showed the presence of collagen and formation of fibrotic scars and inflammation; the signs which are characterized for liver cirrhosis.

We found that CCl<sub>4</sub> caused systemic oxidative stress along with liver damage, reverberating on erythrocytes. This effect was evident by increased protein carbonyl, which is a stable marker of oxidative stress. Since CCl<sub>4</sub> is a hepatotoxin, it seems that this oxidative stress is secondary to liver injury. Protein carbonylation is one of the major physical changes which occurs in the early stages of oxidative stress and has more stability as compared to other parameters of oxidative stress such as glutathione disulfide and MDA. Thus, Protein Carbonyl (CO) groups have been suggested as biomarkers of oxidative stress (21). Lipid peroxidation which produces MDA is one of the basic reactions involved in the oxidative deterioration of polyunsaturated lipids (46), and MDA is also a marker of oxidative damage to membrane lipids. Systemic oxidative stress has been shown to be associated with liver cirrhosis (47) and the increased oxidative markers in different stages of liver damage has been previously reported by this group (48). However, whether liver amelioration is accompanied by a gradual improvement in these markers has not been investigated before.

NTX is an endogenous opioids receptor blocker (49),

and is available as a safe generic formulation already used as an adjunct in counseling treatment of alcohol abuse (50,51), although with FDA's black box label warning of hepatotoxicity (52). Co-treatment of NTX with CCl<sub>4</sub> during the time course of the study could moderately prevent the severe liver injury and significantly decrease the liver enzyme activities of plasma as compared to CCl<sub>4</sub> group. Here we showed for the first time that NTX was able to dramatically diminish protein carbonyl content in erythrocyte membrane during liver injury progression and bring it back to normal levels after 8 weeks.

In this study, MDA levels were not significantly increased in cirrhotic rats compared to control. However, NTX could partially decrease MDA levels as compared to CCl<sub>4</sub> group apparently by protecting the liver from oxidative stress caused by CCl<sub>4</sub>.

Different mechanisms have been proposed for the anti-oxidative function of NTX. Several studies suggest that NTX modulates oxidative stress by increasing GSH level which is suppressed by increased endogenous opioids during liver disease through an unknown mechanism (33). Evidence supporting this concept comes from the studies in which intracerebroventricular injection of an opioid agonist decreased hepatic GSH synthesis (53), suggesting the involvement of endogenous opioids in the regulation of redox state of hepatocytes (54).

In order to investigate whether the beneficial effects of NTX is mediated by GSH, we measured GSH levels in erythrocytes during cirrhosis progression and treatment with NTX. NTX increased erythrocyte GSH levels significantly, especially after 8 weeks of treatment. It could also transiently increase protein sulfhydryl content in the erythrocyte membrane. Cells must be maintained at a high level of reduced GSH. GSH plays a key role in detoxification of xenobiotics in cells, maintenance of oxidative balance and keeping proteins in the reduced state. Alterations of redox status play both direct and indirect roles in the pathogenesis of cirrhosis. GSH depletion has been shown to be associated with loss of protein sulfhydryls (22). There are conflicting reports about the extent of protein sulfhydryl depletion during CCl<sub>4</sub>-induced cirrhosis. One report found significant global protein sulfhydryl depletion during hepatotoxicity (55), whereas others identified only selective protein sulfhydryl alterations (56) or no significant change in protein sulfhydryl status (57). In this study, it was shown that although protein sulfhydryl levels were not significantly different between cirrhotic and normal rats, NTX could increase

protein sulfhydryl levels in cirrhotic rats concomitantly with GSH levels surge in the 6th week. Thus it seems that protein sulfhydryl content is related to GSH levels. The data suggests that during hepatic injury, NTX has beneficial effects in ameliorating the oxidative stress and subsequent pathologic alterations. However, further studies are needed to confirm the effectiveness of NTX in the management of hepatic cirrhosis.

The results of the present study showed that the oxidative stress was higher in CCl<sub>4</sub>-induced cirrhotic rats, and this situation is reflected in altered oxidative stress markers in erythrocytes. NTX had a protective effect on liver damage as well as systemic oxidative status evident by reduced protein carbonyl formation in erythrocyte membrane, slightly decreased MDA production, and increased GSH and protein sulfhydryl levels in erythrocytes. Our findings confirm an anti-oxidative role for NTX and suggest that amelioration of liver cirrhosis can be followed by evaluation of oxidative stress markers, especially protein carbonyl content of erythrocytes.

## Acknowledgment

Authors are grateful to the Research Council of Tehran University of Medical Sciences (Grant No. 19392). We also appreciate Professor Gholamreza Hasanzadeh for his valuable assistance in providing the histological data and the photographs.

## References

- Mokdad AA, Lopez AD, Shahrzaz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Med* 2014;12:145.
- Williams R. Global challenges in liver disease. *Hepatology* 2006;44:521-6.
- Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F, et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. *J Hepatol* 1994;20:531-6.
- Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. *Gastroenterology* 2013;144:512-27.
- Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). *Int J Oncol* 2013;42:1133-8.
- Coulouarn C, Clément B. Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma. *J Hepatol* 2014;60:1306-9.
- Manns MP. Liver cirrhosis, transplantation and organ shortage. *Dtsch Arztebl Int* 2013;110:83-4.
- Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol* 2004;41:935-42.
- Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, De Lédighen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. *Liver Int* 2009;29:242-7.
- Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. *Gastroentérol Clin Biol* 2008;32:22-39.
- Castéra L, Sebastiani G, Le Bail B, de Lédighen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. *J Hepatol* 2010;52:191-8.
- Geetha A, Lakshmi Priya M, Jeyachristy SA, Surendran R. Level of oxidative stress in the red blood cells of patients with liver cirrhosis. *Indian J Med Res* 2007;126:204-10.
- Rosa DPd, Bona S, Simonetto D, Zettler C, Marroni CA, Marroni NP. Melatonin protects the liver and erythrocytes against oxidative stress in cirrhotic rats. *Arq Gastroenterol* 2010;47:72-8.
- Grattagliano I, Giudetti A, Grattagliano V, Palmieri V, Gnoni G, Lapadula G, et al. Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. *Eur J Clin Invest* 2003;33:868-74.
- Moustafa AHA, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. *Eur J Intern Med* 2009;20:703-8.
- Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. *J Hepatol* 2002;37:56-62.
- Catalá A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. *Chem Phys Lipids* 2009;157:1-11.
- Barcia JM, Flores-Bellver M, Muriach M, Sancho-Pelluz J, Lopez-Malo D, Urdaneta AC, et al. Matching Diabetes and Alcoholism: Oxidative Stress, Inflammation, and Neurogenesis Are Commonly Involved. *Mediators Inflamm* 2015;2015:624287.
- Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. *Eur J Intern Med* 2009;20:703-8.

## Erythrocytes membrane in cirrhotic rats

20. Halliwell B, Gutteridge J. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. *Arch Biochem Biophys* 1986;246:501-14.
21. Pandey KB, Rizvi SI. Markers of oxidative stress in erythrocytes and plasma during aging in humans. *Oxid Med Cell Longev* 2010;3:2-12.
22. Yang X, Greenhaw J, Shi Q, Roberts DW, Hinson JA, Muskhelishvili L, et al. Mouse liver protein sulfhydryl depletion after acetaminophen exposure. *J Pharmacol Exper Ther* 2013;344:286-94.
23. Ghezzi A, Visconti P, Abruzzo PM, Bolotta A, Ferreri C, Gobbi G, et al. Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features. *PLoS One* 2013;8:e66418.
24. Manjrekar A, Jisha V, Bag P, Adhikary B, Pai M, Hegde A, et al. Effect of *Phyllanthus niruri* Linn. treatment on liver, kidney and tests in CCl<sub>4</sub> induced hepatotoxic rats. *Indian J Exp Biol* 2008;46:514-20.
25. Ranawat L, Bhatt J, Patel J. Hepatoprotective activity of ethanolic extracts of bark of *Zanthoxylum armatum* DC in CCl<sub>4</sub> induced hepatic damage in rats. *J Ethnopharmacol* 2010;127:777-80.
26. Morakinyo A, Oludare GO AA, Adegoke O. Protective effects of alpha lipoic acid on carbon tetrachloride-induced liver and kidney damage in rats. *Br J Pharmacol Toxicol* 2012;3:21-8.
27. Lee C, Park S, Kim YS, Kang SS, Kim JA, Lee SH, et al. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. *Biol Pharm Bull* 2007;30:1898-904.
28. Wang T, Sun N-L, Zhang W-D, Li H-L, Lu G-C, Yuan B-J, et al. Protective effects of dehydrocavidine on carbon tetrachloride-induced acute hepatotoxicity in rats. *J Ethnopharmacol* 2008;117:300-8.
29. Fang H-L, Lai J-T, Lin W-C. Inhibitory effect of olive oil on fibrosis induced by carbon tetrachloride in rat liver. *Clin Nutr* 2008;27:900-7.
30. Basu S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. *Toxicology* 2003;189:113-27.
31. Khan RA, Khan MR, Sahreen S. Evaluation of *Launaea procumbens* use in renal disorders: A rat model. *J Ethnopharmacol* 2010;128:452-61.
32. Javadi-Paydar M, Ghiassy B, Ebadian S, Rahimi N, Norouzi A, Dehpour AR. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. *Behav Pharmacol* 2013;24:195-206.
33. Kiani S, Ebrahimkhani MR, Sharifabrizi A, Doratotaj B, Payabvash S, Riazi K, et al. Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis. *J Gastroenterol Hepatol* 2007;22:406-13.
34. De Minicis S, Candelaresi C, Marzioni M, Saccomano S, Roskams T, Casini A, et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. *Gut* 2008;57:352-64.
35. Marzioni M, Alpini G, Saccomanno S, De Minicis S, Glaser S, Francis H, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. *Gastroenterology* 2006;130:1831-47.
36. Almansa I, Barcia JM, López-Pedrajas R, Muriach M, Miranda M, Romero FJ. Naltrexone Reverses Ethanol-Induced Rat Hippocampal and Serum Oxidative Damage. *Oxid Med Cell Longev* 2013;2013:296898.
37. Restellini S, Alaei M, Matthes T, Kherad O, Moschetta A, Spahr L. Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open label pilot trial. *Hepatol Res* 2015;45:890-7.
38. Dodge JT, Mitchell C, Hanahan DJ. The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. *Arch Biochem Biophys* 1963;100:119-30.
39. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. *J Biol Chem* 1949;177:751-66.
40. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz A-G, et al. Determination of carbonyl content in oxidatively modified proteins. *Methods Enzymol* 1990;186:464-78.
41. Habeeb A. Reaction of protein sulfhydryl groups with Ellman's reagent. *Methods Enzymol* 1972;25:457-64.
42. Drabkin D, Austin J. Spectrophotometric studies: Spectrophotometric constants for common hemoglobin derivatives in human, dog and rabbit blood. *J Biol Chem* 1932;98:719.
43. Buege JA, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol* 1978;52:302.
44. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. *Trends Neurosci* 1985;8:22-6.
45. de Andrade Belo MA, Soares VE, de Souza LM, da Rosa Sobreira MF, Cassol DMS, Toma SB. Hepatoprotective treatment attenuates oxidative damages induced by carbon tetrachloride in rats. *Exp Toxicol Pathol* 2012;64:155-65.
46. Selvi S, Umadevi P, Suja S, Sridhar K, Chinnaswamy P. Inhibition of in vitro lipid peroxidation (LPO) evoked by *Calocybe indica* (Milky Mushroom). *Anc Sci Life* 2006;26:42-5.
47. Choi J, Ou J-HJ. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. *Am J Physiol Gastroint Liver Physiol* 2006;290:G847-51.

48. Doustimotlagh AH, Dehpour AR, Nourbakhsh M, Golestani A. Alteration in Membrane Protein, Antioxidant Status and Hexokinase Activity in Erythrocytes of CCl<sub>4</sub>-Induced Cirrhotic Rats. *Acta Med Iran* 2014;52:795-803.
49. Faramarzi N, Abbasi A, Tavangar SM, Mazouchi M, Dehpour AR. Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats. *J Gastroenterol Hepatol* 2009;24:1226-9.
50. Brewer KL, Troendle MM, Pekman L, Meggs WJ. Naltrexone prevents delayed encephalopathy in rats poisoned with the sarin analogue diisopropylfluorophosphate. *Am J Emerg Med* 2013;31:676-9.
51. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R. Research to practice: adoption of naltrexone in alcoholism treatment. *J Subst Abuse Treat* 2003;24:1-11.
52. Day SA, Lakner AM, Moore CC, Yen M-H, Clemens MG, Wu ES, et al. Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation. *Biochem Pharmacol* 2011;81:996-1003.
53. Zhang YT, Zheng QS, Pan J, Zheng RL. Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. *Basic Clin Pharmacol Toxicol* 2004;95:53-8.
54. Ebrahimkhani MR, Kiani S, Oakley F, Kendall T, Sharifabrizi A, Tavangar SM, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. *Gut* 2006;55:1606-16.
55. Tirmenstein MA, Nelson SD. Acetaminophen-induced oxidation of protein thiols. Contribution of impaired thiol-metabolizing enzymes and the breakdown of adenine nucleotides. *J Biol Chem* 1990;265:3059-65.
56. Andringa KK, Bajt ML, Jaeschke H, Bailey SM. Mitochondrial protein thiol modifications in acetaminophen hepatotoxicity: effect on HMG-CoA synthase. *Toxicol Lett* 2008;177:188-97.
57. Smith CV, Mitchell JR. Acetaminophen hepatotoxicity *in vivo* is not accompanied by oxidant stress. *Biochem Biophys Res Commun* 1985;133:329-36.